Insulet (PODD) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.28% |
| Dec 31, 2025 | 60.90% |
| Sep 30, 2025 | 23.25% |
| Jun 30, 2025 | 49.40% |
| Mar 31, 2025 | 81.55% |
| Dec 31, 2024 | 25.75% |
| Sep 30, 2024 | 28.34% |
| Jun 30, 2024 | 44.25% |
| Mar 31, 2024 | 68.24% |
| Dec 31, 2023 | 8.23% |
| Sep 30, 2023 | 28.71% |
| Jun 30, 2023 | 55.80% |
| Mar 31, 2023 | 16.19% |
| Dec 31, 2022 | 18.29% |
| Sep 30, 2022 | 19.49% |
| Jun 30, 2022 | 7.09% |
| Mar 31, 2022 | 8.90% |
| Dec 31, 2021 | -26.74% |
| Sep 30, 2021 | -63.37% |
| Jun 30, 2021 | 37.82% |
| Mar 31, 2021 | -27.26% |
| Dec 31, 2020 | 23.85% |
| Sep 30, 2020 | 38.27% |
| Jun 30, 2020 | 102.00% |
| Mar 31, 2020 | -0.63% |
| Dec 31, 2019 | 59.06% |
| Sep 30, 2019 | 45.18% |
| Jun 30, 2019 | 93.83% |
| Mar 31, 2019 | 53.03% |
| Dec 31, 2018 | 60.51% |
| Sep 30, 2018 | 33.82% |
| Jun 30, 2018 | -27.74% |
| Mar 31, 2018 | -28.87% |
| Dec 31, 2017 | 42.69% |
| Sep 30, 2017 | 54.31% |
| Jun 30, 2017 | 29.32% |
| Mar 31, 2017 | -19.65% |
| Dec 31, 2016 | 35.79% |
| Sep 30, 2016 | 39.07% |
| Jun 30, 2016 | 19.19% |
| Mar 31, 2016 | -5.98% |
| Dec 31, 2015 | -19.27% |
| Sep 30, 2015 | 21.79% |